化學治療引起的周邊神經病變之簡介

An Introduction of Chemotherapy-Induced Peripheral Neuropathy

10.3966/168395442015121502006

郭孟慈(Meng-Tzu Kuo)；許心恬(Hsin-Tien Hsu)

化學治療 ； 周邊神經病變 ； Chemotherapy ； Peripheral neuropathy

腫瘤護理雜誌

15卷2期（2015 / 12 / 01）

69 - 82

繁體中文

化學治療是非常重要的癌症治療方式，而化學治療引起的周邊神經病變（Chemotherapy-Induced Peripheral Neuropathy，CIPN）發生率大約10-100%，除了會影響癌症病人日常生活、社交活動或造成情緒困擾外，當CIPN症狀變嚴重時，病人則須減少藥物劑量的施打或暫停治療；但即使停藥，CIPN症狀仍可能會持續一段時間後才逐漸減輕，而有些藥物所產生的症狀，則為不可逆或不會緩解。目前醫護人員及病人普遍對CIPN的認知不足，常常忽略此症狀的存在，因此，希望透過此文章提供CIPN機轉、臨床表徵、危險因子、預防處置及護理照護的資訊，讓醫護人員對於CIPN有完整的認識，且能事先教導病人辨認CIPN可能產生的症狀及瞭解CIPN對其日常生活的影響。護理人員不僅可透過執行身體評估、有效症狀處置及病人教育，並參與跨團隊合作，以提供病人完善的居家照護，進而提升癌症病人的照護及生活品質。

Chemotherapy has been one of the main treatments used to fight cancer. The incidence of chemotherapy-induced peripheral neuropathy (CIPN), however, is approximately 10-100%. This condition can interfere with daily life, social activities and can cause emotional distress. In addition, it is common in practice to reduce the dosage or delay the administration of the next cycle of chemotherapy in response to worsened CIPN symptom. CIPN may lessen over time, but it’s a gradual process that requires several months to resolve. Unfortunately, in some cases, the damage is irreversible or may not diminish in intensity. Health professionals have little understanding about CIPN, and its existence is often overlooked. We hope this article will provide useful information of CIPN mechanism, signs/symptoms, risk factors, preventions and nursing managements to health professionals. Patients can identify their symptoms and understand the impact of CIPN on their life through education by nurses. Excellent home care services for cancer patients could be developed through nursing assessment, effective symptom management and patient education, and through the cooperation of the multi-disciplinary team to improve the care and quality of life.

1. Albers, J. W.,Chaudhry, V.,Cavaletti, G.,Donehower, R. C.(2011).Interventions for preventing neuropathy caused by cisplatin and related compounds.The Cochrane Database of Systematic Reviews,2,CD005228.
2. Argyriou, A. A.,Bruna, J.,Marmiroli, P.,Cavaletti, G.(2012).Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.Critical Reviews in Oncology/Hematology,82(1),51-77.
3. Argyriou, A. A.,Koltzenburg, M.,Polychronopoulos, P.,Papapetropoulos, S.,Kalofonos, H. P.(2008).Peripheral nerve damage associated with administration of taxanes in patients with cancer.Critical Reviews in Oncology/Hematology,66(3),218-228.
4. Argyriou, A. A.,Polychronopoulos, P.,Iconomou, G.,Chroni, E.,Kalofonos, H. P.(2008).A review on oxaliplatin-induced peripheral nerve damage.Cancer Treatment Reviews,34(4),368-377.
5. Armstrong, T.,Almadrones, L.,Gilbert, M. R.(2005).Chemotherapy-induced peripheral neuropathy.Oncology Nursing Forum,32(2),305-311.
6. Bakitas, M. A.(2007).Background noise: the experience of chemotherapy-induced peripheral neuropathy.Nursing Research,56(5),323-331.
7. Balducci, S.,Iacobellis, G.,Parisi, L.,Di Biase, N.,Calandriello, E.,Leonetti, F.,Fallucca, F.(2006).Exercise training can modify the natural history of diabetic peripheral neuropathy.Journal of Diabetes and its Complications,20(4),216-223.
8. Calhoun, E. A.,Welshman, E. E.,Chang, C. H.,Lurain, J. R.,Fishman, D. A.,Hunt, T. L.,Cella, D.(2003).Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.International Journal of Gynecological Cancer,13(6),741-748.
9. Cavaletti, G.,Alberti, P.,Frigeni, B.,Piatti, M.,Susani, E.(2011).Chemotherapy-induced neuropathy.Current Treatment Options in Neurology,13(2),180-190.
10. Cavaletti, G.,Frigeni, B.,Lanzani, F.,Mattavelli, L.,Susani, E.,Alberti, P.,Bidoli, P.(2010).Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.European Journal of Cancer,46(3),479-494.
11. Cavaletti, G.,Marmiroli, P.(2010).Chemotherapy-induced peripheral neurotoxicity.Nature Reviews Neurology,6(12),657-666.
12. Cornblath, D. R.,Chaudhry, V.,Carter, K.,Lee, D.,Seysedadr, M.,Miernicki, M.,Joh, T.(1999).Total neuropathy score: validation and reliability study.Neurology,53(8),1660-1664.
13. Devita, V. T.,Lawrence, T. S.,Rosenberg, S. A.,Depinho, R. A.,Weinberg, R. A.(2011).Devita, Hellman, and Rosenberg’s Cancer: Principles and Practice of oncology.Philadelphia, PA:Lippincott Williams & Wilkins.
14. Forst, T.,Nguyen, M.,Forst, S.,Disselhoff, B.,Pohlmann, T.,Pfutzner, A.(2004).Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device.Diabetes, Nutrition & Metabolism,17(3),163-168.
15. Griffith, K. A.,Merkies, I. S.,Hill, E. E.,Cornblath, D. R.(2010).Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties.Journal of the Peripheral Nervous System,15(4),314-325.
16. Hagiwara, H.,Sunada, Y.(2004).Mechanism of taxane neurotoxicity.Breast Cancer,11(1),82-85.
17. Hausheer, F. H.,Schilsky, R. L.,Bain, S.,Berghorn, E. J.,Lieberman, F.(2006).Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.Seminars in Oncology,33(1),15-49.
18. Huang, H. Q.,Brady, M. F.,Cella, D.,Fleming, G.(2007).Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study.International Journal of Gynecological Cancer,17(2),387-393.
19. Hughes, R.(2008).Peripheral nerve diseases: the bare essentials.Practical Neurology,8(6),396-405.
20. Jiang, H.,Shi, K.,Li, X.,Zhou, W.,Cao, Y.(2006).Clinical study on the wrist-ankle acupuncture treatment for 30 cases of diabetic peripheral neuritis.Journal of Traditional Chinese Medicine,26(1),8-12.
21. Kaley, T. J.,Deangelis, L. M.(2009).Therapy of chemotherapy-induced peripheral neuropathy.British Journal of Haematology,145(1),3-14.
22. Kane, N. M.,Oware, A.(2012).Nerve conduction and electromyography studies.Journal of Neurology,259(7),1502-1508.
23. Kumar, D.,Alvaro, M. S.,Julka, I. S.,Marshall, H. J.(1998).Diabetic peripheral neuropathy. Effectiveness of electrotherapy and amitriptyline for symptomatic relief.Diabetes Care,21(8),1322-1325.
24. Kumar, D.,Marshall, H. J.(1997).Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation.Diabetes Care,20(11),1702-1705.
25. Lavoie Smith, E. M.,Barton, D. L.,Qin, R.,Steen, P. D.,Aaronson, N. K.,Loprinzi, C. L.(2013).Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire.Quality of Life Research
26. Lee, E. Q.,Arrillaga-Romany, I. C.,Wen, P. Y.(2012).Neurologic complications of cancer drug therapies.Continuum: Lifelong Learning in Neurology,18(2),355-365.
27. Lee, J. J.,Swain, S. M.(2006).Peripheral neuropathy induced by microtubule-stabilizing agents.Journal of Clinical Oncology,24(10),1633-1642.
28. Lindsay, K. W.,Bone, I.,Fuller, G.(2010).Neurology and Neurosurgery Illustrated.Edinburgh, UK:Churchill Livingstone.
29. Lipton, R. B.,Apfel, S. C.,Dutcher, J. P.,Rosenberg, R.,Kaplan, J.,Berger, A.,Schaumburg, H. H.(1989).Taxol produces a predominantly sensory neuropathy.Neurology,39(3),368-373.
30. McWhinney, S. R.,Goldberg, R. M.,McLeod, H. L.(2009).Platinum neurotoxicity pharmacogenetics.Molecular Cancer Therapeutics,8(1),10-16.
31. Mileshkin, L.,Prince, H. M.(2006).The trouble some toxicity of peripheral neuropathy with thalidomide.Leukemia & Lymphoma,47(11),2276-2279.
32. National Cancer Institute. (2010, June). Common Terminology Criteria for Adverse Events(CTCAE) Version 4.03. Retrieved from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
33. Piccolo, J.,Kolesar, J. M.(2014).Prevention and treatment of chemotherapy-induced peripheral neuropathy.American Journal of Health-System Pharmacy,71(1),19-25.
34. Postma, T. J.,Aaronson, N. K.,Heimans, J. J.,Muller, M. J.,Hildebrand, J. G.,Delattre, J. Y.,Group, E. Q. o. L.(2005).The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.European Journal of Cancer,41(8),1135-1139.
35. Richardson, J. K.,Thies, S. B.,DeMott, T. K.,Ashton-Miller, J. A.(2004).Interventions improve gait regularity in patients with peripheral neuropathy while walking on an irregular surface under low light.Journal of the American Geriatrics Society,52(4),510-515.
36. Richardson, P. G.,Delforge, M.,Beksac, M.,Wen, P.,Jongen, J. L.,Sezer, O.,Sonneveld, P.(2012).Management of treatment-emergent peripheral neuropathy in multiple myeloma.Leukemia,26(4),595-608.
37. Stubblefield, M. D.,McNeely, M. L.,Alfano, C. M.,Mayer, D. K.(2012).A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.Cancer,118(8 Suppl),2250-2260.
38. Tofthagen, C.(2010).Patient perceptions associated with chemotherapy-induced peripheral neuropathy.Clinical Journal of Oncology Nursing,14(3),E22-E28.
39. Tofthagen, C.,Visovsky, C. M.,Hopgood, R.(2013).Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management.Clinical Journal of Oncology Nursing,17(2),138-144.
40. Topp, K. S.,Tanner, K. D.,Levine, J. D.(2000).Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat.The Journal of comparative neurology,424(4),563-576.
41. Velasco, R.,Bruna, J.(2010).Chemotherapy-induced peripheral neuropathy: an unresolved issue.Neurologia,25(2),116-131.
42. Visovsky, C.,Collins, M.,Abbott, L.,Aschenbrenner, J.,Hart, C.(2007).Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy.Clinical Journal of Oncology Nursing,11(6),901-913.
43. Wickham, R.(2007).Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice.Clinical Journal of Oncology Nursing,11(3),361-376.
44. Widmaier, E. P.,Raff, H.,Strang, K. T.(2011).Vander’s Human Physiology: The Mechanisms of Body Function.New York,NY:McGraw-Hill.
45. Windebank, A. J.,Grisold, W.(2008).Chemotherapy-induced neuropathy.Journal of the Peripheral Nervous System,13(1),27-46.
46. 衛生福利部（2013）.101年死因統計結果分析：十三、惡性腫瘤 .取自http://www.mohw.gov.tw/cht/DOS/DisplayStatisticFile.aspx?d=13689&s=1 [Ministry of Health and Welfare, Taiwan, ROC. (2013). 2012 statistics of causes of death: XIII. Malignant neoplasms. Retrieved from http://www.mohw.gov.tw/cht/DOS/DisplayStatisticFile.aspx?d=13689&s=1]

1. 蘇靖幃、許心恬、孫婉娜、申子蘋(2018)。運用實證探討口服麩醯胺對癌症病人接受化學治療引起的周邊神經病變之成效。護理雜誌，65(1)，61-69。
2. 楊婷婷,紀慧真(2021)。一位乳癌手術患者首次接受化學治療引起周邊神經病變之護理經驗。腫瘤護理雜誌，21(增訂刊II)，57-68。